Photo by marceloleal80 from unsplash
Coronavirus disease 2019 (COVID‐19) in immunocompromised patients can lead to severe and prolonged illness. Data are limited with regard to management of COVID‐19 in this setting, particularly in persistent or… Click to show full abstract
Coronavirus disease 2019 (COVID‐19) in immunocompromised patients can lead to severe and prolonged illness. Data are limited with regard to management of COVID‐19 in this setting, particularly in persistent or recrudescent infection. The authors conducted an online survey among infectious diseases doctors to determine current approaches to treatment across Australasia. There was marked variability in responses relating to the diagnostic modalities and use of antiviral agents in patients with immunocompromise, highlighting the need for high‐quality studies to guide treatment decisions in this group.
Journal Title: Internal Medicine Journal
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!